Outcome of 3 years of immunosuppression with XXXX in more than 1,000 renal transplant recipients in japan.

@entity1 @entity1011 @entity6910 @entity1140
BACKGROUND: In Japan, the new macrolide immunosuppressant, @entity1140 , was approved for the prevention and treatment of allograft rejection in renal transplant recipients in April 1996. This article summarizes efficacy and safety data for @entity1140 gathered since its approval. METHOD: Data from 1,007 @entity1 who received @entity1140 -based treatment after kidney transplantation at 35 leading Japanese transplant centers between April 1996 and December 2000 were retrospectively analyzed. RESULTS: The renal transplants consisted of 856 living (756 @entity6910 compatible, 100 @entity6910 incompatible) and 151 cadaveric (146 non-heart-beating, 5 brain dead) donor grafts. Mean follow-up duration was 24.4 months. Overall @entity1 and graft survival rates were 98.4% and 94.8% at 1 year, 98.0% and 92.6% at 2 years, and 97.6% and 90.4% at 3 years, respectively. Graft survival rates in living and non-heart-beating donor graft transplantations were 95.9% and 88.8% at 1 year, 94.0% and 85.0% at 2 years, and 92.2% and 80.0% at 3 years, respectively. Graft survival rates in living @entity6910 -compatible donor graft transplantation ranged from 93.4% to 97.5%, and in @entity6910 -incompatible cases, rates were stable at 83.2% throughout the 3-year assessment period. Median serum @entity1011 levels ranged from 1.30 to 1.37 mg/dL during this time. Percentages of patients receiving antihyperlipidemics, antihypertensives, and insulin were 12.6%, 41.1%, and 6.5% at 1 year, respectively, and remained low at 3 years after transplantation. CONCLUSION: Three years of @entity1140 therapy demonstrated excellent efficacy and safety in more than 1,000 renal transplant recipients, including recipients of living @entity6910 -incompatible and non-heart-beating donor grafts, with favorable graft function maintained.
